Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Ital

Related Keywords

Baylor College Of Medicine ,Texas ,United States ,Spain ,France ,Germany ,Poland ,Italy ,Polish ,Snehal Patel ,Nasdaq ,Company Contact ,Greenwich Lifesciences Inc ,Redchip Companies Inc ,Exchange Commission ,Company Twitter ,Baylor College ,Breast Cancer ,Greenwich Lifesciences ,Greenwich Lifescience Annual Report ,Public Relations Contact ,Nc ,Phase Iii Clinical Trial ,The Company ,Clinical Trial ,Iopharmaceutical Company ,Greenwich ,Europe ,